logo
Twitter
Discord
Email
logo
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

NASDAQ•FENC
CEO: Mr. Rostislav Raykov
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-09-15
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Contact Information
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, 27709, United States
919-636-4530
www.fennecpharma.com
Market Cap
$211.03M
P/E (TTM)
-30.8
37
Dividend Yield
--
52W High
$9.92
52W Low
$4.68
52W Range
57%
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$12.46M+78.69%
4-Quarter Trend

EPS

-$0.02-90.48%
4-Quarter Trend

FCF

$1.49M-167.68%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

PEDMARK Sales Growth Strong PEDMARK net product sales reached $30.9M for nine months, up $9.2M from $21.7M in prior year period.
Q3 Net Loss Significantly Narrows Third quarter net loss reduced to $(638K) USD, a substantial improvement from $(5.7M) USD loss reported in Q3 2024.
Norgine Royalty Revenue Stream Recognized $390K USD in Norgine royalties within product sales for the nine months ended September 30, 2025.
Ending Cash Position Secure Cash and equivalents totaled $21.9M USD as of September 30, 2025, supporting near-term operations.

Risk Factors

Operating Cash Flow Negative Nine months ended September 30, 2025 showed net cash used in operating activities of $(6.5M) USD compared to inflow.
Ongoing Patent Litigation Risk Active patent infringement suit against CIPLA entities continues, posing potential legal and financial uncertainty.
Accumulated Deficit Large Accumulated deficit reached $(224.6M) USD as of September 30, 2025, impacting overall equity position.
Reliance on Single Product Business heavily relies on PEDMARK commercialization success; future growth tied to market penetration efforts.

Outlook

Norgine European Expansion Norgine announced launch of PEDMARQSI in Germany and U.K. early 2025, expanding market reach.
Strategic Alternatives Pursued Company continues pursuing strategic alternatives, including collaborations, to fund future capital requirements and R&D efforts.
Term Loan Maturity Approaching Remaining Second Closing Notes principal balance of approximately $19.5M USD (inclusive of PIK) matures in August 2027.
Patent Defense Efforts Continue Actively defending key PEDMARK patents against generic challenges, including recent filing of suit against CIPLA.

Peer Comparison

Revenue (TTM)

Enanta Pharmaceuticals, Inc.ENTA
$65.32M
-3.4%
Entrada Therapeutics, Inc.TRDA
$61.52M
-71.4%
Fennec Pharmaceuticals Inc.FENC
$38.79M
-21.4%

Gross Margin (Latest Quarter)

Enanta Pharmaceuticals, Inc.ENTA
100.0%
+0.0pp
Assembly Biosciences, Inc.ASMB
100.0%
+0.0pp
Fennec Pharmaceuticals Inc.FENC
94.7%
+14.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SLS$449.02M-17.8-95.2%1.2%
TRDA$436.85M-4.6-26.4%12.7%
EPRX$301.32M-11.8-62.6%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
16.3%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:$0.01
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 13, 2025|
    Revenue: $12.46M+78.7%
    |
    EPS: $-0.02-90.5%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $9.65M+32.9%
    |
    EPS: $-0.12-40.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $8.75M-65.5%
    |
    EPS: $-0.04-109.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 26, 2025|
    Revenue: $47.54M+123.7%
    |
    EPS: $-0.02+97.3%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $6.97M+7.0%
    |
    EPS: $-0.21+200.0%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $7.26M+118.4%
    |
    EPS: $-0.20-4.8%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $25.38M+1413.2%
    |
    EPS: $0.47-262.1%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 29, 2024|
    Revenue: $21.25M+1284.5%
    |
    EPS: $-0.60+36.8%
    Miss